Table 2.
β-Lactams, β-lactamase inhibitors, and β-lactams/β-lactamase inhibitor combinations in development.
| Compounds | Chemical classes | Bacteria profile | Indication (Company) | (Pre)-Clinical phase |
|---|---|---|---|---|
| CXA-201 (ceftolozane/tazobactam) | cephalosporin/sulfone penam | G+, G− | cUTI, cIAI; HABP/VABP (Cubist) | III, Completed II |
| CAZ104 (ceftazidime/avibactam) | cephalosporin/diazabicyclooctane | G+, G− | cIAI; UTI (AstraZeneca) | III |
| CXL (ceftaroline/avibactam) | cephalosporin/diazabicyclooctane | G+, G− | MRSA (AstraZeneca) | III |
| Imipenem/cilastatin/MK-7655 | carbapenem/DHP-I inhibitor/diazabicyclooctane | G+, G− | UTI and cIAI (Merck) | II |
| BAL30072 | monobactam | G+, G− | Gram-negative (Basilea) | I |
| S-649266 (GSK-2696266) | cephalosporin | G+, G− | Gram-negative infections (Shionogi/GSK) | I |
| ATM-AVI (aztreonam/avibactam) | monobactam/diazabicyclooctane | G+, G− | Metallo β-lactamase producers (AstraZeneca) | I |
| Carbavance (biapenem/RPX7009) | carbapenem/Boronic acid | G+, G− | KPC, CRE (The Medicines Company, previously Rempex) | II |
| TD-1792 | glycopeptide-cephalosporin hybrid | G+ | (Theravance) | II-III |
| FPI-1465 | diazabicyclooctane | Fedora | Discovery | |
| Novel β-lactamase inhibitors | sulphonamides | (John Hopkins Un.) | Discovery | |
| Novel β-lactamase inhibitors | Boronic acid | (John Hopkins Un.) | Discovery | |
| Novel β-lactamase inhibitors | Boronic acid | (Therabor Pharmaceuticals) | Discovery | |
| MG96077 | phosphonate-based β-lactamase inhibitor | (Mirati Therapeutics) | Discovery | |
| CB-027 | cephalosporin | G+, G− | MRSA, P. aeruginosa (Cubist) | Discovery |
| FSI-1671 | carbapenem | G− | (FOB Synthesis Inc.) | Discovery |